Research programme: Tau antibody therapeutics - Axon Neuroscience
Latest Information Update: 14 Jan 2026
At a glance
- Originator Axon Neuroscience
- Class Antibodies; Antidementias
- Mechanism of Action Tau protein modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Alzheimer's disease; Tauopathies
Most Recent Events
- 12 Jan 2026 Early research in Alzheimer's disease in Slovakia (Parenteral) prior to January 2026 (Axon Neuroscience pipeline; January 2026)
- 12 Jan 2026 Early research in Tauopathies in Slovakia (Parenteral) prior to January 2026 (Axon Neuroscience pipeline; January 2026)